3-Fucosyllactose and 3′-sialyllactose combined with Lacticaseibacillus rhamnosus 1.0320 alleviate necrotizing enterocolitis by modulating the gut microbiota and regulating NF-κB/Nrf2 pathways

Key Points

• This research aims to investigate how 3-fucosyllactose and 3'-sialyllactose combined with Lacticaseibacillus rhamnosus can alleviate necrotizing enterocolitis.
• Administered 3-fucosyllactose and 3'-sialyllactose along with Lacticaseibacillus rhamnosus to premature infants.
• Monitored gut microbiota composition and assessed NF-κB and Nrf2 pathway regulation.
• Evaluated clinical outcomes related to necrotizing enterocolitis.
• Significant improvement in gut microbiota diversity observed post-intervention.
• Reduction in disease severity as measured by clinical markers (p<0.05).
• Enhanced regulation of NF-κB and Nrf2 pathways linked to reduced inflammation.